Orikine Bio

About Orikine Bio

Orikine Bio is a biotechnology company that is a spin-off from the Centre for Genomic Regulation (CRG) in Barcelona. The company is focused on developing a new generation of cytokine-based therapies for autoimmune and inflammatory diseases.

Orikine Bio has developed a proprietary platform of protein design and engineering called Foldikines©. This platform allows the company to create engineered cytokines with improved biological activities. These Foldikines© are designed to be more effective and have fewer side effects than existing cytokine-based therapies.

The company's business model is based on the development and commercialization of its Foldikine©-based therapies. Orikine Bio plans to partner with pharmaceutical companies to bring its products to market. The company's primary customers are patients with autoimmune and inflammatory diseases.

Orikine Bio is currently in the preclinical stage of development. The company's lead product candidate, ORK-1, is a Foldikine©-based therapy for the treatment of Inflammatory Bowel Disease (IBD). Orikine Bio has secured €5.5 million in seed financing to advance its pipeline and bring its therapies to the clinic.